KRAS and cancer: The results indicated that TMEM59L expression was closely correlated with cancer-related hallmarks, including epithelial-mesenchymal transition (EMT), P53 pathway, E2F target, cell cycle regulation at G2-M, KRAS signaling, WNT beta-catenin signaling, and immune-related pathways, such as TGF-β, IL2-STAT5, and TNFα signaling via NF-kB.